The US Food and Drug Administration (FDA) has approved an alternative formulation for Neurocrine Biosciences’ Huntington’s disease therapy, Ingrezza (valbenazine). The new formulation ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback